Type 2 diabetes is one of the most common diseases worldwide and is closely linked to modern lifestyle. But recent research is revealing something surprising: the health of your gut microbiota—the billions of bacteria living in your intestines—can influence your risk of developing this condition.
Multiple studies show that certain probiotics, such as Bacillus subtilis DG101 (the strain used in Kyojin), can have a highly positive effect on people with type 2 diabetes. Similar bacteria to those found in Kyojin’s probiotic (Bacillus subtilis) are also present in traditional fermented foods like Korean chungkookjang and Japanese natto—both known for their health benefits for centuries.
In recent clinical cases involving hundreds of patients in Argentina, individuals with type 2 diabetes who were not responding well to conventional medications showed significant improvements in blood sugar and HbA1c levels after adding Kyojin probiotic to their diet. In one case, a 74-year-old woman with obesity and high glucose levels reduced her values to near-normal. In another, a man with impaired pancreatic function improved his blood sugar and HbA1c levels in just four months.
This suggests that the probiotic Bacillus subtilis DG101 may help the body respond better to insulin, allowing for more natural and effective control of blood glucose levels.
At Kyojin, we believe that nutrition can be a powerful ally for health. Our probiotic is not a cure, but it can be a valuable complement for those managing type 2 diabetes.
Related Papers:
- Tuomi T, Santoro N, Caprio S, Cai M, Weng J, Groop L. The many faces of diabetes: a disease with increasing heterogeneity. Lancet. 2014; 22(383):1084-94.
- Olle B. Medicines from microbiota. Nature Biotechnol. 2013; 31(4): 309-315.
- Scott K, Antoine J, Midtvedt T, van Hemert S. Manipulating the gut microbiota to maintain health and treat disease. Microb. Ecol. Health Dis. 2015; 26(25877): 10.3402/mehd.v26.25877.
- Panwar H, Rashmi HM, Batish VK, Grover S. Probiotics as potential biotherapeutics in the management of type 2 diabetes—prospects and perspectives. Diabetes Metab. Res. Rev. 2013; 29(2):103–112.
- Do Yeon Jeong, Dailly J, Gaeho Lee, y col. Short-term fermented soybeans with Bacillus amyloliquefaciens potentiated insulin secretion capacity and improving gut microbiome diversity and intestinal integrity to alleviate type 2 diabetic symptoms. J. Agric. Food Chem. 2020; doi 10.1021/acs.jafc.9b07962.
- Cardinali N, Bauman C, Rodriguez Ayala F, Grau R. Two cases of type 2 diabetes mellitus successfully treated with probiotics. Clin. Case Rep. 2020; doi 10.1002/ccr3.3354.
- Ayala FR, Cardinali N, Grau R. Efficient Weight Loss and Type II Diabetes Control in Overweight and Obese Patients Consuming the Probiotic Bacillus Subtilis DG101: A Randomized Double-Blind Placebo-Controlled Study. Asp Biomed Clin Case Rep. 2022 Apr 04;5(1):51-58.
- Ayala FR, Cardinali N, Grau R. Effectiveness of the probiotic Bacillus subtilis DG101 to treat type 2 diabetes mellitus triggered by SARS-CoV-2 infection. J Clin Images Med Case Rep. 2022; 3(5): 1847.
- Tonucci LB, Olbrich Dos Santos KM, Licursi de Olivera L, Rocha Ribeiro SM, Duarte Martino HS. Clinical application of probiotics in type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study. Clin Nutr. 2017; 36(1): 85-92.